LEGEND BIOTECH CORPORATION

(LEGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/23/2022 05/24/2022 05/25/2022 05/26/2022 05/27/2022 Date
39.95(c) 39.03(c) 39.16(c) 39.35(c) 42.73 Last
476 854 240 371 167 179 285 930 381 227 Volume
-6.24% -2.30% +0.33% +0.49% +8.59% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 144 M - -
Net income 2022 -423 M - -
Net cash position 2022 553 M - -
P/E ratio 2022 -22,3x
Yield 2022 -
Sales 2023 283 M - -
Net income 2023 -314 M - -
Net cash position 2023 819 M - -
P/E ratio 2023 -24,7x
Yield 2023 -
Capitalization 6 590 M 6 590 M -
EV / Sales 2022 42,0x
EV / Sales 2023 20,4x
Nbr of Employees 1 071
Free-Float 5,97%
More Financials
Company
Legend Biotech Corporation. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, LCAR- B38M (cilta-cel), is an autologous CAR-T cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in a number of hematologic malignancies, including multiple... 
Sector
Biotechnology & Medical Research
Calendar
06/04 | 09:00amPresentation
More about the company
Ratings of Legend Biotech Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D
More Ratings
All news about LEGEND BIOTECH CORPORATION
05/26LEGEND BIOTECH : CARVYKTI« (ciltacabtagene autoleucel) Granted Conditional Approval by the..
PU
05/26Legend Biotech Receives Conditional European Commission Approval for Multiple Myeloma D..
MT
05/26CARVYKTI« (ciltacabtagene autoleucel) Granted Conditional Approval by the European Comm..
BU
05/26European Commission Grants Marketing Authorization to CARVYKTI of Legend Biotech Corpor..
CI
05/18Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma Wit..
BU
05/10Genscript Biotech's Nasdaq-listed Unit Promotes Finance VP to CFO; Shares Slip 5%
MT
05/09Legend Biotech Names New CFO
MT
05/09Legend Biotech Appoints Lori Macomber as Chief Financial Officer
BU
05/09Legend Biotech Appoints Lori Macomber as Chief Financial Officer
CI
05/06Legend Biotech Announces Participation in Upcoming Investor Conferences
BU
04/22Genscript Biotech Unit Receives $50 Million Milestone Payment from Janssen Biotech
MT
04/21Legend Biotech Gets $50 Million Milestone Payment Under Deal With Janssen Biotech for C..
MT
04/21LEGEND BIOTECH : Achieves Milestone Under Collaboration Agreement with Janssen Biotech, In..
PU
04/21Legend Biotech Achieves $50 Million Milestone Payment Under Janssen Deal
DJ
04/03Legend Biotech Announces Executive Changes
CI
More news
News in other languages on LEGEND BIOTECH CORPORATION
05/26CARVYKTI« (Ciltacabtagene Autoleucel) erhält von der Europäischen Kommission bedingte Z..
05/26Le CARVYKTI« (ciltacabtagène autoleucel) reçoit l'approbation conditionnelle de la Comm..
05/26Legend Biotech reçoit l'approbation conditionnelle de la Commission européenne pour un ..
05/26La Commission européenne accorde une autorisation de mise sur le marché à CARVYKTI de L..
05/10L'unité de Genscript Biotech cotée au Nasdaq promeut le vice-président des finances au ..
More news
Analyst Recommendations on LEGEND BIOTECH CORPORATION
More recommendations
Chart LEGEND BIOTECH CORPORATION
Duration : Period :
Legend Biotech Corporation Technical Analysis Chart | LEGN | US52490G1022 | MarketScreener
Technical analysis trends LEGEND BIOTECH CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 42,73 $
Average target price 66,43 $
Spread / Average Target 55,5%
EPS Revisions
Managers and Directors
Ying Huang Chief Executive Officer & Director
Lori Macomber Chief Financial Officer
Ye Wang Chairman
Guowei Fang SVP, Global Head-Research & Early Development
Corazon Dating Sanders Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LEGEND BIOTECH CORPORATION-8.32%6 069
GILEAD SCIENCES, INC.-11.21%80 866
REGENERON PHARMACEUTICALS, INC.8.22%73 638
VERTEX PHARMACEUTICALS22.79%68 965
BIONTECH SE-38.65%38 433
WUXI APPTEC CO., LTD.-22.01%37 870